• Users Online: 407
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 17  |  Issue : 3  |  Page : 314-318

Evaluation of intravitreal ranibizumab injection as a line of treatment for chronic central serous retinopathy


Department of Ophthalmology, Faculty of Medicine, Al-Azhar University, Assiut, Egypt

Correspondence Address:
Emad A.A Saliem
MD Ophthalmology, Tahta, Sohag, Egypt; Lecturer of Ophthalmology, Department of Ophthalmology, Faculty of Medicine, Al-Azhar University, Assiut, 71524
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/AZMJ.AZMJ_112_19

Rights and Permissions

Background To assess the effectiveness of ranibizumab in the treatment of chronic central serous retinopathy (CCSR). Patients and methods This prospective study included 10 eyes of 10 patients with CCSR treated by a single dose of ranibizumab injected intravitreally. After injection, the patients were re-evaluated at the second day, then after 1 week, and then monthly up to 6 months. Changes in vision and macular thickness were detected before and after injection. Results The main best-corrected visual acuity increased from 0.82±0.08 logMAR before injection to 0.56±0.09 logMAR after 3 months and to 0.24±0.09 logMAR after 6 months in patients with CCSR less than 6 months, and increased from 0.78±0.16 logMAR before injection to 0.64±0.15 logMAR after 3 months and to 0.36±0.09 logMAR after 6 months in those with CCSR more than or equal to 6 months (P<0.05). The mean central macular thickness decreased from 342±36.14 μm before injection to 252±7.02 μm after 3 months and to 204±17.13 μm after 6 months in patients with CCSR less than 6 months, and decreased from 322±51.42 μm before injection to 259±26.06 μm after 3 months and to 214±18.13 μm after 6 months (P<0.05) in those with CCSR more than or equal to 6 months. The mean age of patients was 39±9.6 years. Conclusion The use of ranibizumab for treatment CCSR was more clinically effective and generally well tolerated.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed286    
    Printed16    
    Emailed0    
    PDF Downloaded37    
    Comments [Add]    

Recommend this journal